Zoryl MP 1 Forte Tablet SR is a combination oral antihyperglycemic medication containing Glimepiride (1mg), Metformin (1000mg), and Pioglitazone (15mg), formulated for sustained release. This tablet is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release formulation ensures gradual drug release, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Zoryl MP 1 Forte Tablet SR should be used as part of a comprehensive diabetes management plan including diet and exercise. Monitoring of blood glucose levels, renal function, and liver enzymes is recommended during therapy. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to any component. Patient adherence and regular follow-up are essential to optimize therapeutic outcomes and minimize adverse effects.